Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated
11/06/2026 09:27
BRIEF-Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated June 11 (Reuters) - Cipla Ltd CIPL.NS:
USFDA CLASSIFIED VERNA MANUFACTURING FACILITY INSPECTION AS VOLUNTARY ACTION INDICATED
Source text: ID:nnAZN4T1SB5
Further company coverage: CIPL.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate